Welcome to our dedicated page for Tabula Rasa Heal news (Ticker: TRHC), a resource for investors and traders seeking the latest updates and insights on Tabula Rasa Heal stock.
Tabula Rasa HealthCare reports developments tied to medication safety, personalized pharmacy services and technology-enabled care management for value-based healthcare organizations. The company offers precision medication management and delivery, clinical and business management tools, and services used by health plans, at-risk provider groups and Programs of All-Inclusive Care for the Elderly.
Recurring TRHC updates include operating and financial results, PACE customer agreements, pharmacy benefit management services, MedWise medication-risk technology, PACElogic integrated technology solutions and PeakTPA administration services. Corporate news also covers governance changes, material agreements, shareholder voting matters and capital-structure disclosures.
Tabula Rasa HealthCare (TRHC) has partnered with Equiscript to enhance medication adherence analytics for community health centers and hospitals. This collaboration aims to deliver detailed adherence reports and Star ratings to Equiscript’s clients, improving patient outcomes and risk mitigation. TRHC's clinical algorithms will help identify patients needing medication reviews, thus optimizing medication safety. The 340B Program underpins this initiative, aiming to maximize resources and services for eligible patients.
Tabula Rasa HealthCare (NASDAQ: TRHC) announced a partnership with Regence to conduct a virtual clinical trial assessing adverse drug events (ADEs) related to COVID-19 drug repurposing. The study will analyze de-identified data from around 500,000 Regence health plan members, employing TRHC's MedWise technology to evaluate medication risks. The results are expected within 60 days, contributing critical safety information for COVID-19 treatments. Regence serves 3.1 million members across several states, emphasizing a commitment to improving healthcare during the pandemic.
Tabula Rasa HealthCare (TRHC) has signed a Letter of Intent with ASCP to enhance medication safety for older adults. This partnership will allow ASCP's pharmacist members to access TRHC's MedWise technology, aimed at optimizing medication regimens and reducing adverse drug events. ASCP CEO Chad Worz emphasized the value of MedWise in improving care for senior patients. TRHC’s CEO, Calvin Knowlton, highlighted that the collaboration aims to cut healthcare costs and strengthen pharmacist-patient relationships while addressing medication-related issues effectively.
Tabula Rasa HealthCare (TRHC) reported its Q1 2020 financial results, showcasing total revenue of $72.8 million, a 19% increase year-over-year. This figure aligns closely with guidance expectations. However, Non-GAAP Adjusted EBITDA decreased 16% to $4.8 million, attributed to increased investments and COVID-19 related expenses. Despite these challenges, the company recorded a significant 102% increase in bookings compared to last year, driven largely by new partnerships. Revenue guidance for the full year remains steady, indicating resilience amid ongoing market uncertainties.
Summary not available.